Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Glaucoma, Open Angle, Low Risk, Ocular Hypertension, Glaucoma Suspect
Interventions: Mercury™ Multi-Pressure Dial (MPD) Experimental Goggle, Mercury™ Multi-Pressure Dial (MPD) Placebo Goggle; Device
Lead sponsor: Vance Thompson Vision; Other
Eligibility: 22 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Pulmonary Arterial Hypertension
Interventions: Sotatercept, Background PAH Therapy; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 9
States / cities: Phoenix, Arizona • Aurora, Colorado • Indianapolis, Indiana + 6 more

Conditions: Exercise-induced Pulmonary Arterial Hypertension
Interventions: Ambrisentan; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: Akron Children's Hospital; Other
Eligibility: 7 Years to 21 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Hypertensive Heart Disease, Hypertension
Interventions: More intensive CHW Intervention, Less Intensive CHW Intervention; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 25 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension
Interventions: LCZ696, Olmesartan, LCZ696 matching placebo, Olmesartan matching placebo, amlodipine, hydrochlorothiazide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 60 Years and older
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 11
States / cities: Clearwater, Florida • Chicago, Illinois • Baltimore, Maryland + 8 more

Conditions: Hypertensive Disorder of Pregnancy
Interventions: Nifedipine ER; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Pulmonary Arterial Hypertension
Interventions: Protein Elisa analysis, microRNA analysis, whole exome sequencing; Diagnostic Test
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 2 Years to 17 Years
Enrollment: 40 participants
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Hypertension, Type 2 Diabetes Mellitus
Interventions: Nebivolol, Metoprolol ER, HCTZ; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 62
States / cities: Athens, Alabama • Huntsville, Alabama • Bell Gardens, California + 54 more

Conditions: Hypertension
Interventions: Health coaching, Health coaching plus home titration; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 30 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hypertension
Interventions: UPLIFT, Usual care; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Thromboembolic Pulmonary Hypertension
Interventions: Selexipag, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 32
States / cities: La Jolla, California • Los Angeles, California • Aurora, Colorado + 25 more

Conditions: Hypertension
Interventions: barbershop-based BP measurement; Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Heart Failure, Pulmonary Arterial Hypertension
Interventions: right heart catheterization; Diagnostic Test
Lead sponsor: Silverleaf Medical Sciences INC; Industry
Eligibility: 20 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Chronic Disease, Hypertension, Hyperlipidemia, Diabetes Mellitus, Osteoarthritis, COPD, Cardiovascular Disease
Interventions: Patient Primer Tool; Behavioral
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Aortic Stenosis, Mitral Regurgitation, Pulmonary Hypertension, Heart Failure, Systolic, Cardiovascular Diseases, Coronary Artery Disease
Interventions: MindMics earbud; Other
Lead sponsor: Scripps Health; Other
Eligibility: Not listed
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: PG286 Ophthalmic Solution 0.5%, AR-12286 Ophthalmic Solution 0.5%, Travoprost Ophthalmic Solution 0.004%; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 21
States / cities: Artesia, California • Inglewood, California • Newport Beach, California + 18 more

Conditions: Gastrointestinal Hemorrhage, Portal Hypertension
Interventions: Thalidomide; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Metabolic Syndrome
Interventions: simvastatin, ezetimibe/simvastatin; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 21 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Baltimore, Maryland

Conditions: Pulmonary Hypertension
Interventions: Sildenafil citrate; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 33
States / cities: La Jolla, California • Los Angeles, California • San Diego, California + 21 more

Conditions: Age-related Macular Degeneration, Diabetic Retinopathy, Hypertensive Retinopathy, Retinal Vein Occlusion, Retinal Artery Occlusion
Interventions: Phase variance optical coherence tomography (PV-OCT); Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pregnancy Complications, Obesity, Pre-Eclampsia, Gestational Diabetes
Interventions: Resistance exercise, Aerobic Exercise, Rest; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Stroke, Transient Ischemic Attack
Interventions: tailored intervention, attention placebo; Behavioral
Lead sponsor: Narrows Institute for Biomedical Research; Other
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Severe Hypertension, Hypertension
Interventions: Emergency Department-Initiated Team-Based Care, Usual Care; Other
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 85 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 4
States / cities: Dearborn, Michigan • Detroit, Michigan • Wyandotte, Michigan

Search by objective public record fields.

Effect of Negative Pressure on Pattern Electroretinography Readings

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)

Serum Brain Natriuretic Peptide Levels and Pulmonary Hypertension in Pediatric Sickle Cell Patients

Asian American Partnerships in Research and Empowerment (AsPIRE)

Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension

Intensive Postpartum Antihypertensive Treatment

Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial Hypertension

Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients

Treating to Target for Patients With Hypertension

Emotional Awareness and SElf-regulation for Depression in Patients With Hypertension (EASE) Study

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment

Cut Your Pressure Too: The Altadena Barbershop Blood Pressure Study, Phase 2 (Intervention Pilot Study)

Non-invasive Pulmonary Artery Prediction (ADOPTS)

A Pilot Study to Improve Patient-Doctor Communication

Evaluating Infrasonic Hemodynography

A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days

Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using THALIDOMIDE

Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment

The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH

Comparison of Phase-variance Optical Coherence Tomography and Fluorescein Angiography in Retinovascular Imaging

Acute Exercise Effects in Obese Pregnancy

The PREVENTS Trial: The Preventing Recurrent Events in Veterans Navigating Transient Ischemic Attack (TIA) or Stroke Trial

Emergency Department-Initiated Team-Based Care for Severe Hypertension